Last checked at 5 Oct 2012 14:07
Port Erin Biopharma Investments Limited ("The Company")
Net Asset Value calculation for the fourth trading quarter to 30th September 2012
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2012 was 9.63 pence per share, including un-invested cash of £329,708. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a useful increase from the previous valuation of 9.46 pence per share, including un-invested cash of £237,391. The revenue reserve has increased substantially following the deduction of listing expenses from the share premium account and represents a return of 16.75% on investments after operating costs."
| Unaudited 15 September 2011 to 30 September 2012 £ | |
Fixed Assets |
|
|
| Investments
| 2,859,129 |
Current Assets |
|
|
| Debtors: amounts owing | 12,414 |
| Un-invested cash
| 329,708 |
Current Liabilities |
|
|
| Creditors: amounts due
| (23,400) |
|
| 3,177,851 |
Capital and Reserves |
|
|
| Share Capital | 33 |
| Share Premium | 2,699,011 |
| Capital reserve - realised | 0 |
| Capital reserve - unrealised | 0 |
| Revenue reserve
| 478,806 |
| 3,177,850 | |
| ||
Shares in Issue
| 33,000,000 | |
Net Asset Value per share
| 9.63 pence |
--- ENDS ---
Portfolio Details
Holdings | £Value | Portfolio % |
| 30/09/2012 |
|
Synergy Pharmaceuticals Inc. | 235,997 | 8.3% |
Pfizer Inc. | 227,368 | 8.0% |
Plethora Solutions Holdings | 199,963 | 7.0% |
Summit Corporation plc | 184,133 | 6.4% |
Gilead Sciences Inc. | 176,372 | 6.2% |
Novartis AG | 170,354 | 6.0% |
Arrowhead Research Corp. | 169,915 | 5.9% |
Astellas Pharmaceuticals Inc. | 157,268 | 5.5% |
Abbott Laboratories | 122,948 | 4.3% |
Nektar Therapeutics | 110,864 | 3.9% |
| 1,755,182 | 61.4% |
|
|
|
Aggregate remaining holdings below 3% of total portfolio | 1,103,947
| 38.6%
|
| 2,859,129 | 100.0% |
For further information, please contact:
Port Erin Biopharma Investments Ltd | Libertas Capital Corporate Finance Limited | Peterhouse Capital Limited |
The Company | Nomad | Broker |
Denham Eke +44 162 463 9396 | Sandy Jamieson +44 207 569 9650 | Jon Levinson +44 207 562 3350 |